Search - tctmd.com

Displaying 161 - 180 of 462

Sort: Relevancy | Date

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Caitlin E. Cox

June 13, 2019

News Conference News SCAI 2019

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

Yael L. Maxwell

May 30, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News EuroPCR 2019

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Michael O'Riordan

May 27, 2019

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Conference News EuroPCR 2019

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Shelley Wood

May 16, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Caitlin E. Cox

March 17, 2019

News Conference News CRT 2019

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Yael L. Maxwell

March 03, 2019

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Todd Neale

January 09, 2019

News Features

Top News in Coronary Artery Disease: 2018

Yael L. Maxwell

December 28, 2018

News Daily News

US and European DAPT Guidelines More Alike Than Different, Say Experts

Yael L. Maxwell

December 03, 2018

News Daily News

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Yael L. Maxwell

November 05, 2018

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Advertisement

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Cancer and CV Disease Care: What’s Known? What Lies Ahead for Cardio-Oncology?

New Clarity on Patients at High Risk for Bleeding After PCI

Daring to Dream: New BRS Data Hint at Low MACE Rates at 2 and 3 Years

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Off to EuroPCR 2019? Expect Mitral and Tricuspid Updates, Thin-Strut Stent Surprises, and ‘Strong’ Statements

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

Rivaroxaban in Addition to DAPT Lowers Death, MI, Stroke in ACS, Heart Failure Patients: Meta-analysis

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

Top News in Coronary Artery Disease: 2018

US and European DAPT Guidelines More Alike Than Different, Say Experts

Debate Over BMS vs DES in High-Bleeding-Risk Scenarios Gets Fresh Fuel in Meta-analysis

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content